Robust, disease-specific datasets in CNS, Cardiometabolic and Inflammatory Disease are powered for statistical significance with multi-omic and whole genome data and detailed longitudinal clinical data.
Accelerating drug target identification, validation, and biomarker discovery
Our disease-specific clinico-omic datasets in CNS, Cardiometabolic and Inflammatory Disease offer genomic data enriched with detailed clinical data and are statistically powered to enhance discovery.
Curated, disease specific, longitudinal deep phenotyped, genomic cohorts in CNS, cardiometabolic and inflammatory disease. Selected cohorts are distinguished by extensive clinical phenotyping, and the highest quality genomic data generation through our purpose-built CAP accredited genomics centre.
The availability of focused multi-omic sub-cohorts to each of our population genomic cohorts enable our clients to combine genetic evidence with biological function to further establish causality and effect.
Powerful analytics crafted for insights
Analytics and AI trained on multi-omic and phenotypic data. Proven in target discovery, drug response signatures and population genomics.
Our Capabilities & Expertise
Target Discovery: Identify novel targets with strong genetic evidence.
Portfolio Optimization: Validate candidate targets or biomarkers and focus investment
Clinical Trials: Design better studies and enrollment criteria by identifying relevant sub-populations